Stifel analyst Thomas Stephan upgraded Staar Surgical to Buy from Hold with a price target of $50, up from $30. The firm says the shares have pulled back notably since its initiation in late 2022 as investor excitement toward EVO’s domestic opportunity has deteriorated. The analyst believes the company’s “conservative” 2024 guidance, U.S. EVO “green-shoots,” and a trough valuation can allow you investors to “weather these storms, at discounted prices for a differentiated asset/technology.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on STAA:
- Staar Surgical’s Financial Performance Conference Overview
- Staar Surgical price target lowered to $45 from $50 at Mizuho
- Staar Surgical price target raised to $32 from $31 at Canaccord
- Staar Surgical price target lowered to $33 from $40 at Piper Sandler
- Staar Surgical sees FY24 revenue $335M-$340M, consensus $348.96M
